{"nctId":"NCT00022516","briefTitle":"Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer","startDateStruct":{"date":"2000-11"},"conditions":["Breast Cancer"],"count":1086,"armGroups":[{"label":"No-CM","type":"NO_INTERVENTION","interventionNames":[]},{"label":"CM-Maintenance","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Drug: Methotrexate"]}],"interventions":[{"name":"Cyclophosphamide","otherNames":["Endoxan","Cytoxan"]},{"name":"Methotrexate","otherNames":["Trexall"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed stage I, II, or III breast cancer\n\n  * T1-3, N0-2, M0\n\n    * Patients with sentinel node biopsy positive disease must have undergone axillary dissection\n    * Tumor must be confined to the breast without detected metastases elsewhere\n  * T4 disease with minimal dermal invasion allowed\n  * No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer\n* No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite breast that has not been proven benign\n* No distant metastases\n\n  * No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT\n* Must have undergone prior total mastectomy OR breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned\n\n  * Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery\n* Negative surgical margins\n* Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy\n* Known HER2 status by immunohistochemistry or fluorescence in situ hybridization\n* Hormone receptor status:\n\n  * Estrogen and progesterone receptor negative\n\n    * Less than 10% positive tumor cells by immunohistochemistry\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Not specified\n\nSex:\n\n* Not specified\n\nMenopausal status:\n\n* Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR\n* Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy (OR age 50 and over)\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* WBC greater than 3,000/mm3\n* Platelet count greater than 100,000/mm3\n\nHepatic:\n\n* See Disease Characteristics\n* Bilirubin less than 2.0 mg/dL\n* ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L\n\nRenal:\n\n* Creatinine less than 1.2 mg/dL\n\nOther:\n\n* Not pregnant or lactating within the past 6 months\n* Fertile patients must use effective barrier contraception\n* No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma\n* No psychiatric or addictive disorders that would preclude study\n* No non-malignant systemic disease that would preclude study\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Prior trastuzumab (Herceptin) allowed\n\nChemotherapy:\n\n* See Disease Characteristics\n* No prior adjuvant or neoadjuvant chemotherapy for breast cancer\n\nEndocrine therapy:\n\n* No prior endocrine therapy for breast cancer or prevention\n* No prior tamoxifen or raloxifene for breast cancer\n\nRadiotherapy:\n\n* No prior radiotherapy for breast cancer except primary irradiation\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* No prior preventative therapy for breast cancer","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival","description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null},{"groupId":"OG001","value":"78.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Distant Recurrence-free Interval","description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free Interval is defined as the time from randomization to invasive breast cancer recurrence at distant site, or invasive contralateral breast cancer; or censored at date of last follow up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null},{"groupId":"OG001","value":"85.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Breast Cancer-free Interval","description":"Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"81.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":["Elevated SGPT","Elevated SGOT","Leukopenia","Nausea","Vomiting"]}}}